Our laboratory is interested in understanding how basic cellular mechanisms become coopted in cancer and in harnessing these insights to improve cancer diagnosis and treatment. We focus on elucidating key drivers of cancer phenotypes, particularly those seen in prostate cancer and bladder cancer. Central to our work is a series of genetically engineered mouse (GEM) models we developed that recapitulate key molecular events associated with the human cancers that they emulate and that facilitate informed mechanistic and preclinical investigations. In parallel we have been using state-of-the-art computational systems biology approaches that enable accurate cross-species analyses of experimental data from GEM models and human cancer. Collectively, our studies have identified novel mechanisms of cancer initiation and progression, biomarkers that hold great potential to inform cancer prognosis, and promising new approaches for cancer treatment and prevention.